Varki Paul's Form 4 filing
Avalo Therapeutics, Inc. (AVTX) · filed May 7, 2026
- Accession no.
- 0001677896-26-000004
- Filed
- May 7, 2026
- Trade date
- May 6, 2026
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Checked
This filing lists 7 non-derivative transactions and 2 derivative transactions. Open-market sales total $1.51M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Varki PaulCIK 0001677896 | Officer (Chief Legal Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 6, 2026 | Common Stock | MOption exerciseAcquired | +62,500 | $13.43 | +$839,375 | 66,134 | Direct | |
| May 6, 2026 | Common Stock | MOption exerciseAcquired | +12,563 | $8.04 | +$101,006.52 | 78,697 | Direct | |
| May 6, 2026 | Common Stock | SSaleDisposed | −37,375 | $18.91F2 | −$706,761.25 | 41,322 | Direct | |
| May 6, 2026 | Common Stock | SSaleDisposed | −5,196 | $19.78F3 | −$102,776.88 | 36,126 | Direct | |
| May 6, 2026 | Common Stock | SSaleDisposed | −22,839 | $21.22F4 | −$484,643.58 | 13,287 | Direct | |
| May 6, 2026 | Common Stock | SSaleDisposed | −9,253 | $22.70F5 | −$210,043.1 | 4,034 | Direct | |
| May 6, 2026 | Common Stock | SSaleDisposed | −400 | $23.71 | −$9,484 | 3,634 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 6, 2026 | Common Stock | MOption exerciseDisposed | −62,500 | $0.00 | $0 | 87,500 | Direct | |
| May 6, 2026 | Common Stock | MOption exerciseDisposed | −12,563 | $0.00 | $0 | 87,437 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The reported securities were sold in multiple transactions at prices ranging from $18.50 to $19.495. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
Referenced by the price of 1 transaction in Table I.
- F3
The reported securities were sold in multiple transactions at prices ranging from $19.50 to $19.99. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
Referenced by the price of 1 transaction in Table I.
- F4
The reported securities were sold in multiple transactions at prices ranging from $20.75 to $21.69. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
Referenced by the price of 1 transaction in Table I.
- F5
The reported securities were sold in multiple transactions at prices ranging from $22.15 to $22.88. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
Referenced by the price of 1 transaction in Table I.